Problem

Cognitive capacity is important but poorly measured over time. Connectome addresses the gap between one-off cognitive tests or subjective behavioural proxies and the need to understand meaningful change in an individual’s brain. The pain is especially acute because cognitive decline can occur silently before traditional diagnostics, while existing longitudinal approaches can involve costly imaging, in-person administration, and outdated or unreliable assessments.

The main use cases are settings where small changes in cognition, fatigue, recovery, or resilience matter: performance environments such as elite sport, preventive and longevity clinics, executive health, and research or technology development. In sport, for example, the killer use case is repeatedly tracking a player’s cognitive function alongside training, travel, workload, and recovery to inform development, fatigue management, injury recovery, and return-to-play decisions.

Product / Service

Connectome presents itself as a cognitive-intelligence platform and longitudinal measurement layer that sits above devices and protocols. It repeatedly measures brain and cognitive signals, combines them with contextual information such as sleep, activity, workload, or training, and establishes a within-person baseline. Results are interpreted against that baseline, with confidence scores and explicit “no signal” states, rather than treating a population average or single assessment as definitive.

The platform is designed for developers, researchers, clinics, and performance teams that need repeatable, interpretable evidence. Its initial delivery model has involved approximately 20-minute, non-invasive fNIRS scans delivered through partner longevity and neuro-performance clinics, while the broader platform can integrate existing behavioural and wearable data. The benefit is a more sensitive and evidence-aware way to evaluate attention, cognitive load, stability, recovery, and changes over time without making diagnostic or clinical claims.

Market

Connectome competes in the emerging neurotechnology, digital brain-health, longitudinal cognitive-assessment, and performance-monitoring markets. Its closest adjacent competitors include Altoida, which provides longitudinal cognitive assessment for clinical research and care, and Linus Health and BrainCheck, which focus on digitally enabled cognitive assessment and clinical workflows. It also competes indirectly with one-off behavioural tests, wearables, and hardware-focused neurotechnology companies such as Kernel and Muse; Connectome’s differentiation is the contextual interpretation of repeated brain measurements rather than simply selling a device or administering a standalone test.

The company is early-stage but has meaningful validation and commercialization signals. In April 2026 it raised approximately $2 million in pre-seed funding, led by Redstone with participation from Concept Ventures, Octopus, strategic investors, and angels, including $120,000 in non-dilutive public funding. The financing was intended to launch the product with selected partners, and Connectome has announced a performance partnership with Como 1907. Revenue is not disclosed in the available evidence, so the company is best characterized as being in early partner rollout rather than having demonstrated scaled commercial traction.